NOT FOR DISTRIBUTION
Header cover image

Extrawell Pharmaceutical Holdings

Market Cap

HK$353.7m

Last Updated

2021/04/17 10:23 UTC

Data Sources

Company Financials

Executive Summary

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. More Details


Snowflake Analysis

Proven track record and fair value.

Share Price & News

How has Extrawell Pharmaceutical Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 858 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 858's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-5.1%

858

-1.5%

HK Pharmaceuticals

0.7%

HK Market


1 Year Return

64.4%

858

18.8%

HK Pharmaceuticals

28.0%

HK Market

Return vs Industry: 858 exceeded the Hong Kong Pharmaceuticals industry which returned 18.8% over the past year.

Return vs Market: 858 exceeded the Hong Kong Market which returned 28% over the past year.


Shareholder returns

858IndustryMarket
7 Day-5.1%-1.5%0.7%
30 Day-11.4%-4.6%-1.2%
90 Day18.4%6.2%1.8%
1 Year64.4%64.4%20.5%18.8%33.4%28.0%
3 Year-3.9%-3.9%-11.0%-16.0%8.1%-3.9%
5 Year-52.3%-52.3%94.1%75.5%56.5%28.9%

Long-Term Price Volatility Vs. Market

How volatile is Extrawell Pharmaceutical Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Extrawell Pharmaceutical Holdings undervalued compared to its fair value and its price relative to the market?

2.65x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 858's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 858's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 858 is good value based on its PE Ratio (2.7x) compared to the HK Pharmaceuticals industry average (12.6x).

PE vs Market: 858 is good value based on its PE Ratio (2.7x) compared to the Hong Kong market (11.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 858's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 858 is good value based on its PB Ratio (0.3x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is Extrawell Pharmaceutical Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Extrawell Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Extrawell Pharmaceutical Holdings performed over the past 5 years?

36.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 858 has a large one-off gain of HK$152.4M impacting its September 30 2020 financial results.

Growing Profit Margin: 858's current net profit margins are higher than last year (74%).


Past Earnings Growth Analysis

Earnings Trend: 858 has become profitable over the past 5 years, growing earnings by 36.1% per year.

Accelerating Growth: 858's earnings growth over the past year (112.2%) exceeds its 5-year average (36.1% per year).

Earnings vs Industry: 858 earnings growth over the past year (112.2%) exceeded the Pharmaceuticals industry 2.7%.


Return on Equity

High ROE: 858's Return on Equity (11.1%) is considered low.


Financial Health

How is Extrawell Pharmaceutical Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 858's short term assets (HK$212.0M) exceed its short term liabilities (HK$58.7M).

Long Term Liabilities: 858's short term assets (HK$212.0M) exceed its long term liabilities (HK$71.9M).


Debt to Equity History and Analysis

Debt Level: 858's debt to equity ratio (5.3%) is considered satisfactory.

Reducing Debt: 858's debt to equity ratio has increased from 4.9% to 5.3% over the past 5 years.

Debt Coverage: 858's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 858's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Extrawell Pharmaceutical Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 858's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 858's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 858's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 858's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 858's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.5yrs

Average board tenure


CEO

Yi Xie (57 yo)

no data

Tenure

HK$1,386,000

Compensation

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...


CEO Compensation Analysis

Compensation vs Market: Yi's total compensation ($USD178.44K) is about average for companies of similar size in the Hong Kong market ($USD227.72K).

Compensation vs Earnings: Yi's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 858's board of directors are seasoned and experienced ( 12.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Extrawell Pharmaceutical Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Extrawell Pharmaceutical Holdings Limited
  • Ticker: 858
  • Exchange: SEHK
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$353.722m
  • Shares outstanding: 2.39b
  • Website: https://www.extrawell.com.hk

Number of Employees


Location

  • Extrawell Pharmaceutical Holdings Limited
  • Devon House
  • Suites 2206-08, 22nd Floor
  • Quarry Bay
  • Hong Kong

Listings


Biography

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. It operates through Manufacturing, Tra...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 10:23
End of Day Share Price2021/04/16 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.